
Uniper reports first hydrogen at 30 MW Bad Lauchstädt plant
About 3,000 tonnes are planned for TotalEnergies' Leuna refinery in 2027 as the partners begin testing the integrated supply chain.

The quantum-computer developer held US$497.1 million in cash and investments as it targeted a larger system for mid-2028.

About 3,000 tonnes are planned for TotalEnergies' Leuna refinery in 2027 as the partners begin testing the integrated supply chain.

Concentrate from Burswood will go to Curtin's C4P facility, with samples intended for assessment before potential refining-partner evaluation.
The Texas test reactor will support equipment trials and operator training after reaching first criticality in August 2026.
Only US$1.5 million is upfront; the balance depends on warrants, with first U.S. patient dosing targeted for the second quarter of 2027.

New breast and lung cancer applications aim to inform therapy choices when conventional mutation markers leave gaps.

The STOXX Europe 600 advanced as AI demand optimism met higher infrastructure spending, with Nvidia results scheduled for Nov. 17.

A US$15M partner payment arrived after quarter-end as research spending rose ahead of the Nov. 28 D-PLEX100 review goal.

TNR holders would receive Altius shares and a stake in an Alaska gold spinout, subject to shareholder, court and exchange approvals.
Excellon would retain 19.9 per cent of the German explorer while shareholders keep their proportionate interest in its Peru-focused business.
Full production is targeted for 2028, with Louisiana offering a performance-based grant and the company planning 175 additional jobs.
Nine-month orders rose 611 per cent, but the third-quarter adjusted EBITDA loss widened to US$37.7 million.
The Army-related opportunity remains subject to lease negotiations, while the reactor developer expects spending on its pilots to increase.
DISA would own about 8.88 per cent after conversion, while a separate share transfer would take IsoEnergy's holding to 22.1 per cent.
Third-quarter capital investment rose to C$1.084 billion as higher costs outweighed gains from approved rates and peak demand.
The first US$200 million draw awaits customer acceptance and other conditions, with borrowing at a minimum 8 per cent before fees.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The Chilean project's infill program will add 3,300 metres to support an updated resource and a pre-feasibility study planned for 2027.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The 17-person sales team precedes planned January 2027 deliveries, with margins above 50 per cent forecast by the company.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
Contracted GPU-cloud run rate includes undeployed capacity, while HIVE's year-end expansion target remains conditional on financing.
Canada and Germany have completed competition reviews, Curaleaf says, while its offer remains outstanding until Dec. 4.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
The sale targets a second-quarter 2027 close and supports additional debt reduction and an expanded share-repurchase plan.

The power producer now expects adjusted earnings of US$12.50 to US$12.80 a share, lifting the midpoint by US$0.65.

BLM's completeness finding leaves pipeline baseline studies and the level of environmental review to be settled before mine-plan approval.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The board accepted its committee's recommendation on Oct. 26, citing the harvest, a stronger outlook and debt repayment.

The submission draws on studies involving more than 1,000 participants, with a first-half 2027 launch still subject to FDA approval.

Operating cash flow reached US$9.5 million as expansion spending eased, but weaker Canadian wholesale pricing reduced cannabis profit.

Free cash outflow narrowed to C$15.5 million as international sales grew, while charges on Canopy USA assets weighed on earnings.